Open AccessErlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient
Author(s) -
Yukari Tsubata,
Akinobu Hamada,
Akihisa Sutani,
Takeshi Isobe
Publication year - 2012
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.95201
Subject(s) - erlotinib , medicine , interstitial lung disease , lung cancer , concomitant , drug , pharmacodynamics , lung , oncology , plasma concentration , pharmacology , pharmacokinetics , cancer , epidermal growth factor receptor
We herein describe a case of drug-induced interstitial lung disease (ILD) following treatment with erlotinib. The plasma trough concentration of erlotinib at the time of the ILD diagnosis was extremely elevated compared with the plasma maximum concentration on day 1. We hypothesized that this phenomenon was associated with the pharmacodynamic interaction with a concomitant drug. The present case indicates that erlotinib-induced ILD was associated with a high plasma concentration of erlotinib. Oncologists should be aware of the possibility of ILD induced by erlotinib, especially for patients with co-morbidities.